Pneumonia News

Today marks World Pneumonia Day, a day during which the Forum of International Respiratory Societies, including the American Thoracic Society, raises awareness about the effect of this disease.

Researchers have found three microRNAs that may predict respiratory failure and sepsis among patients with community-acquired pneumonia.

A 2-day course of prophylactic antibiotic therapy lowered the incidence of early ventilator-associated pneumonia among patients treated with target temperature management after out-of-hospital cardiac arrest, according to results from the ANTHARTIC trial.

The American Diabetes Association, the American Lung Association and the American Heart Association are working together to urge adults living with chronic diseases to prioritize annual influenza vaccination and to encourage health care providers to advocate for and support influenza immunization within their practices, according to a press release from the organizations.

NEW ORLEANS — In-hospital influenza vaccination may reduce 30-day readmissions, mortality, morbidity and health care resource utilization in adults with community-acquired pneumonia.

Despite guidelines recommending its use, pneumococcal urinary antigen testing, or UAT, is not performed often in the United States, even though it can help identify patients who are eligible for antibiotic de-escalation, researchers reported.

Recently updated guidelines for the diagnosis and treatment of adults with community-associated pneumonia, or CAP, stressed the importance of de-escalation of antibiotic therapy and made stricter recommendations on when to use broad-spectrum antibiotics for the treatment of patients with CAP and risk factors for drug-resistant organisms.

Concomitant steroid-pulse treatment and baseline lymphopenia were among risk factors for pneumocystis pneumonia among a cohort of patients with rheumatic diseases receiving steroid treatment, according to findings published in Arthritis Research & Therapy.

WASHINGTON — Cefiderocol, a novel siderophore cephalosporin, was noninferior to high-dose meropenem for the primary endpoint of all-cause mortality 14 days after treatment was started in patients with nosocomial pneumonia caused by gram-negative pathogens, according to results of a randomized phase 3 trial called APEKS-NP.

Today marks World Lung Day, and this year’s theme is “healthy lungs for all.”